Navigation Links
MaxCyte Presents a Panel Discussion With Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery - LIVE Q&A to Follow
Date:12/15/2008

GAITHERSBURG, Md., Dec. 15 /PRNewswire/ --MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces that, due to popular demand, it will be rebroadcasting its webinar with industry experts on the challenges in developing cell-based screening assays for drug discovery. The broadcast is open to the industry and will be held by webinar on Tuesday December 16th at two convenient times, 9:00 AM and 7:30 PM EST. A live Q&A will follow the broadcast.

One of the respected industry experts who led the discussion was Dr. John Reardon, formerly Senior Vice President of Discovery Research Biology at Glaxo Smith Kline and now Executive Vice President and Chief Scientific Officer at Integrated Oncology Solutions Inc. (IOS) in North Carolina. Dr. Reardon reviewed the complexities of cell transfection technologies and challenged the webinar participants to consider the possibilities of creating more relevant assays if it were possible to transfect any molecule into any cell at any scale, while maintaining biological integrity and high quality standards. His discussion offered compelling arguments as to how the MaxCyte(R) STX System can reduce bottlenecks and improve the productivity of drug discovery groups.

Dr. James Brady, Director of Technical Applications at MaxCyte, led the webinar participants through a technical presentation of the MaxCyte(R) STX(TM) Scalable Transfection System. Dr. Brady demonstrated how the MaxCyte STX technology enables the large scale transfection of primary cells, cell lines, and stem cells with single and multiple loading agents at the same time, resulting in more relevant screening systems.

According to MaxCyte CEO Doug Doerfler, "We were delighted with the response to our previous webinar on the MaxCyte STX technology and the interest in continuing with the live panel discussion. The MaxCyte STX is being viewed by the pharmaceutical industry a
'/>"/>

SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
2. MaxCyte to Present at the BIO CEO & Investor Conference
3. MaxCyte to Present at the Phacilitate Cell and Gene Therapy Forum 2008
4. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
5. Medicsight PLC Presents New Data at RSNA 2008 Further Supporting Relevance of Computer-Aided Detection (CAD) and Image Analysis Software in Early Colon Cancer Screening and Diagnosis
6. CVS Caremark Presents Influenza Vaccine Data at Rescheduled 2008 DMAA Annual Meeting
7. Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile
8. Sonic Innovations Presents Donation to the Armed Forces Foundation
9. HMS Presents 4th Annual Heroes of Healthcare Awards
10. HealthEdge(R) Presents Award-Winning HealthRules(R) Technology Platform at the 2008 Gartner Healthcare Summit
11. Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... improve letter formation could boost self-esteem,...lthDay News) -- Autistic children are more likely ...rming letters, than those without autism, research...aged 8 to 13. Half of the study participants had a...cored within the normal range for perceptual reaso...
(Date:11/9/2009)...ZHEN, China, Nov. 9 /PRNewswire-FirstCall/ - Hard ... announced today that Novartis, a US$41 billion in...% stake in HTDS, H1N1 Vaccine partner, Zhejiang Ti...llion. Novartis of Switzerland will begin a five-y...e company will dramatically increase its investmen...
(Date:11/9/2009)... New study highlights positive infl... Rosemont, IL (Vocus) Novembe...bone health decreases. Recent research has highlig...ments to help prevent these issues. However, a new... Sports Health: A Multidisciplinary Approach rev...
(Date:11/9/2009)...rch of Dimes Names 2010 National Ambassador ,...e/ -- Joshua Hoffman of Weston, Fla., was born so ...doctors could not say whether he would survive -- ..., the 6-year-old was named March of Dimes 2010 Nat...fman, recalls, "My first minutes of motherhood and...
(Date:11/9/2009)...y reports some people went from incapacitated to w...lthDay News) -- Electrical stimulation of a certai...nt for severe depression, say German researchers. ...mbens area of the brains of 10 people. This area ...ures that people remember good experiences and put...
Breaking Medicine News(10 mins):Health News:Handwriting Skills May Lag in Kids With Autism 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3Health News:Brain Stimulation May Ease Treatment-Resistant Depression 2
...imaging a lower cost tool than MRI for evaluating ...5 (HealthDay News) -- Researchers say they can che...ugs are at cutting off a tumor,s blood supply by u...thwestern Medical Center team added a molecule sub...
...e University physician Terrie Taylor studies cereb...alaria patients are children. And, in order to get...ld, Taylor and colleagues study the child,s brain,...the first MRI machine ever to come to Malawi will...
...e 5 For the second consecutive year,Farmers Insur...yees have,shattered the single-day fundraising rec... $3.2 million on Tuesday, June 3. The Farmers Insu... than,$2.7 million., (Logo: http://www.newscom.c...
...., June 5 Dynasplint Systems, Inc. --, http://www...34th annual,Severna Park Independence Day Parade a..., the parade begins at St. Martin,s -in-the-field ..., This is the first time Dynasplint, located in S...
... Opposition on Capitol Hill Once Negative Impact o..., Mo., June 5 In thanking U.S.,Senators Kent Conr...erkley,(D-NV), Earl Pomeroy (D-ND) and Shelley Moo...iors, Medicare Part A nursing,home benefits, the C...
..., June 5 Hill-Rom (NYSE: HRC ),has received a Go...talCare(R) Bariatric Plus therapy system. The awar...ing and design. This is the second year in a row,t...s microclimate management, pulmonary management, a...
Other Medicine News:Health News:Tracking Cancer Drug's Effectiveness 2Health News:New MRI to debut in African nation of Malawi; will save lives, advance malaria research 2Health News:New MRI to debut in African nation of Malawi; will save lives, advance malaria research 3Health News:Farmers Insurance Group(R) Raises More Than $3.2 Million in a Single Day for the March of Dimes 2Health News:Farmers Insurance Group(R) Raises More Than $3.2 Million in a Single Day for the March of Dimes 3Health News:Front Line Caregiver Coalition Thanks Sens. Conrad, Coleman and Reps. Pomeroy, Capito and Berkley for Leading Bipartisan Hill Effort to Stop Bush Administration's Damaging Medicare Cuts 2Health News:Hill-Rom Innovative TotalCare(R) Bariatric Plus Therapy System Receives Gold Medical Device Excellence Award 2Health News:Hill-Rom Innovative TotalCare(R) Bariatric Plus Therapy System Receives Gold Medical Device Excellence Award 3
(Date:11/9/2009)...all/ -- Cardiac Science Corporation (Nasdaq: ...brillator ( AED ) and diagnostic cardiac monitor...ion for the third quarter ended September 30, 2009...also recorded a charge of $18.5 million for an AED....0 million to increase its valuation allowance aga...
(Date:11/9/2009)... 9 Hill-Rom (NYSE: HR...ion of a joint venture that will focus on the sale...ace replacement systems that are intended to be so...or surfaces that are technologically obsolete or a...l leader in patient support systems and related te...
(Date:11/9/2009)...all/ -- Landauer, Inc. (NYSE: LDR ), a recogniz...monitoring services, today announced the completio...term strategic priorities. ,, "We are pleased t...tions, Inc. (GPS) and Gammadata Mattenknik AB (GDM...er. "These acquisitions position Landauer to execu...
Breaking Medicine Technology:Cardiac Science Announces Third Quarter Results 2Cardiac Science Announces Third Quarter Results 3Cardiac Science Announces Third Quarter Results 4Cardiac Science Announces Third Quarter Results 5Cardiac Science Announces Third Quarter Results 6Cardiac Science Announces Third Quarter Results 7Cardiac Science Announces Third Quarter Results 8Cardiac Science Announces Third Quarter Results 9Cardiac Science Announces Third Quarter Results 10Cardiac Science Announces Third Quarter Results 11Cardiac Science Announces Third Quarter Results 12Cardiac Science Announces Third Quarter Results 13Cardiac Science Announces Third Quarter Results 14Cardiac Science Announces Third Quarter Results 15Cardiac Science Announces Third Quarter Results 16Cardiac Science Announces Third Quarter Results 17Cardiac Science Announces Third Quarter Results 18Cardiac Science Announces Third Quarter Results 19Cardiac Science Announces Third Quarter Results 20Hill-Rom and Encompass Group Form Joint Venture 2Hill-Rom and Encompass Group Form Joint Venture 3Hill-Rom and Encompass Group Form Joint Venture 4Hill-Rom and Encompass Group Form Joint Venture 5Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 2Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 3Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 4Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 5SourceMedical 26apos 3Bs Therapy Software Partners with FOTO the Leading Provider of Patient Outcome Surveys 14463 1SourceMedical 26apos 3Bs Therapy Software Partners with FOTO the Leading Provider of Patient Outcome Surveys 14463 2SourceMedical 26apos 3Bs Therapy Software Partners with FOTO the Leading Provider of Patient Outcome Surveys 14463 3Baptist Medical Center 26apos 3Bs Patient Outcomes Among Highest in the Nation According to Independent Study 59425 1Baptist Medical Center 26apos 3Bs Patient Outcomes Among Highest in the Nation According to Independent Study 59425 2Baptist Medical Center 26apos 3Bs Patient Outcomes Among Highest in the Nation According to Independent Study 59425 3Baptist Medical Center 26apos 3Bs Patient Outcomes Among Highest in the Nation According to Independent Study 59425 4One Day Management Training Program to be Offered November 18 in Boston Area 59420 1One Day Management Training Program to be Offered November 18 in Boston Area 59420 2One Day Management Training Program to be Offered November 18 in Boston Area 59420 3One Day Management Training Program to be Offered November 18 in Boston Area 59420 4One Day Management Training Program to be Offered November 18 in Boston Area 59420 5
...nificant reduction in sedation during the,early po...stically significant reduction in nausea in the fe...bridge, UK, 8th June 2007 - CeNeS Pharmaceuticals ...cal company, announces,additional data from post-h... of M6G (morphine-6-glucuronide) in over 500 patie...
...BUSINESS WIRE)--Jun 8, 2007 - NuPathe Inc., a,priv... announced,positive results from an initial Phase ...r acute migraine being developed,by NuPathe., NP10...ontophoretic transdermal technology with sumatript... migraine in the United,States. Sumatriptan is als...
Other Medicine Technology:Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 2Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 3Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 4Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 5Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 6Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 7NuPathe Reports Positive Phase One Results for NP101 Transdermal,Therapy for Acute Migraine 2NuPathe Reports Positive Phase One Results for NP101 Transdermal,Therapy for Acute Migraine 3
ALLEGRO Analyzer
RESTASIS®
LADARWave® Aberrometer
ZYMAR™ 2.5 mL
Medicine Products: